Hemorheological parameters, such as WBV and fibrinogen, coupled with AChE-RBC may be useful biomarkers for disease progression evaluations and the therapeutic monitoring of AD patients that can be used instead of invasive inspections. Here, ACHE is linked to Alzheimer disease.